Long Ideas - With Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively … Continue Reading
Read NowLong Ideas - Nektar Therapeutics (NASDAQ:NKTR) hosted a conference call Monday morning, highlighting the successful results from two Phase III trials and one safety extension study for Naloxegol, … Continue Reading
Read NowLong Ideas - Earnings for Amarin Corp. (NASDAQ:AMRN) were primarily focused on the company’s strategy for the launch of Vascepa, as well as the FDA’s decision on whether … Continue Reading
Read NowLong Ideas - Esbriet (perfenidone) sales in Europe have begun to pick up according to InterMune’s (NASDAQ:ITMN) third quarter results, driven largely (91%) by sales in Germany where … Continue Reading
Read NowLong Ideas - The past few months have been eventful ones for Biogen Idec (NASDAQ:BIIB), as the company awaits the FDA’s decision on BG-12 and continues to build … Continue Reading
Read NowLong Ideas - Merge Healthcare (NASDAQ:MRGE) is back in the news with Reuters reporting that the company’s plan to explore strategic alternatives has attracted at least five private … Continue Reading
Read NowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) updated investors Thursday morning on both its Zerenex development program and its 3Q financials, reiterating that pivotal Phase 3 data for the … Continue Reading
Read Now